普萘洛尔片剂口服治疗婴幼儿血管瘤68例临床分析

摘要

目的 探讨口服普萘洛尔片剂方法治疗婴幼儿血管瘤的临床疗效及安全性.方法 2011年11月-2015年6月在门诊就诊的68例血管瘤患儿,接受普萘洛尔片剂治疗(每日总量1.5 ～2 mg/kg,分3～4次口服,一周加至足量);观察记录血管瘤大小、颜色的变化以及相关副作用,以评价其疗效及安全性.结果 服药3个月、6个月、1年治疗有效率分别为88.2％、98.1％、98.1％;疗效达Ⅴ级及以上者分别为33.8％、80.8％、100％.多数患儿在治疗12个月时已经停药,继续用药的患儿,其疗效分级均为Ⅵ级.疗效与性别、开始服药月龄、病灶部位均无关(P＞0.05).本组3例患儿出现一过性普洛萘尔相关不良反应,停药后恢复.结论 口服普萘洛尔方法治疗婴幼儿血管瘤疗效显著、副作用少.%Objective To investigate the clinical efficacy and safety of propranolol in the treatment of infantile hemangioma.Methods Oral propranolol was administered in 68 infants who were admitted to our hospital from October 2011 to June 2015,at dosage of 1.5mg ～ 2mg/(kg · d),3 ～4 times a week,plus enough.The changes of tumor size texture and color were monitored and recorded.For the safety study,side reactions were also recorded.Results The responsive rate to therapy at 3,6 and 12 months were 88.2％,98.1％ and 98.1％,repectively,with 33.8％,80.8％ and 100％,respectively reached class Ⅴ or higher grade efficacy.Most children had stopped treatment at 12 months,and those only got class Ⅵ efficacy needed longer therapy.The efficacy was not associated with gender,age and location of the disease.3 of 67 were noted to have light side reactions.Conclusions Propranolol is capable of curing infantile hemangiomas,or promoting its regression in some paitents,with less side reactions.